Lyra Therapeutics, Inc. (LYRA)
USD 0.17
(-6.54%)
USD 0.17
(-6.54%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -63.3 Million | -43.38 Million | -25.82 Million | -21.14 Million | -13.75 Million | -6.64 Million |
| Net Income | -62.68 Million | -55.27 Million | -43.51 Million | -22.12 Million | -16.3 Million | -6.02 Million |
| Depreciation & Amortization | 278 Thousand | 1.06 Million | 1 Million | 95 Thousand | 27 Thousand | 82 Thousand |
| Deferred income taxes | -450 Thousand | - | -2.42 Million | - | - | - |
| Stock-based compensation | 5.88 Million | 5.44 Million | 2.77 Million | 1.81 Million | 244 Thousand | 406 Thousand |
| Change in working capital | -4.88 Million | 4.55 Million | 13.92 Million | -879 Thousand | 2.11 Million | 79 Thousand |
| Other non-cash items | -1.45 Million | 824 Thousand | 2.42 Million | -45 Thousand | 167 Thousand | -1.17 Million |
| Investing Cash Flow | -12.58 Million | -65 Million | -3.38 Million | -1.77 Million | -211 Thousand | -37 Thousand |
| Investments in PPE | -1.04 Million | -164 Thousand | -3.38 Million | -1.77 Million | -211 Thousand | -37 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -122.42 Million | -64.84 Million | - | - | - | - |
| Sales/Maturities of investments | 110.88 Million | - | - | - | - | - |
| Other Investing Activities | -1.00 | -64.84 Million | - | - | - | - |
| Financing Cash Flow | 65.69 Million | 96.25 Million | 359 Thousand | 87.7 Million | -115 Thousand | 29.21 Million |
| Debt repayment | - | - | - | - | - | -500 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 65.69 Million | 100.49 Million | 604 Thousand | 59.89 Million | 111 Thousand | 12 Thousand |
| Other Financing Activities | -3.65 Million | -4.23 Million | -245 Thousand | 27.81 Million | -226 Thousand | 29.21 Million |
| Accounts receivables | - | - | - | - | - | 164 Thousand |
| Accounts payables | 450 Thousand | -2.41 Million | 2.35 Million | 345 Thousand | -205 Thousand | 134 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -5.33 Million | 6.96 Million | 11.57 Million | -1.22 Million | 2.31 Million | -55 Thousand |
| Cash at beginning of period | 32.54 Million | 46.07 Million | 74.92 Million | 10.13 Million | 24.21 Million | 1.68 Million |
| Cash at end of period | 22.35 Million | 33.94 Million | 46.07 Million | 74.92 Million | 10.13 Million | 24.21 Million |
| Capital Expenditure | -1.04 Million | -164 Thousand | -3.38 Million | -1.77 Million | -211 Thousand | -37 Thousand |
| Effect of forex changes on cash | 1.00 | - | - | - | - | - |
| Net cash flow / Change in cash | -10.19 Million | -12.13 Million | -28.84 Million | 64.78 Million | -14.08 Million | 22.53 Million |
| Free Cash Flow | -64.35 Million | -43.54 Million | -29.2 Million | -22.91 Million | -13.96 Million | -6.67 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -48.13 Million | -22.45 Million | -15.15 Million | -62.68 Million | -15.65 Million | -15.61 Million |
| Depreciation & Amortization | 145 Thousand | 136 Thousand | 85 Thousand | 278 Thousand | -68 Thousand | -23 Thousand |
| Deferred income taxes | - | - | -5.18 Million | -450 Thousand | - | - |
| Stock-based compensation | 1.12 Million | 2.16 Million | 1.48 Million | 5.88 Million | 1.44 Million | 1.35 Million |
| Change in working capital | 2.69 Million | -1.36 Million | -4.38 Million | -4.88 Million | 1.22 Million | -961 Thousand |
| Other non-cash items | 23.22 Million | 2.06 Million | 4.09 Million | -1.45 Million | -1.05 Million | 966 Thousand |
| Investing Cash Flow | 36.17 Million | 7.85 Million | -2.35 Million | -12.58 Million | -14.97 Million | -561 Thousand |
| Investments in PPE | -196 Thousand | -2.14 Million | -787 Thousand | -1.04 Million | -144 Thousand | -71 Thousand |
| Acquisitions | - | - | -9.96 Million | - | 14.83 Million | 490 Thousand |
| Investment purchases | -14.61 Million | -20.52 Million | -49.65 Million | -122.42 Million | -42.83 Million | -25.49 Million |
| Sales/Maturities of investments | 50.98 Million | 30.53 Million | 48.08 Million | 110.88 Million | 28 Million | 25 Million |
| Other Investing Activities | 36.37 Million | 10 Million | -1.57 Million | -1.00 | -14.83 Million | -490 Thousand |
| Financing Cash Flow | -89 Thousand | 8.64 Million | 18.92 Million | 65.69 Million | -418 Thousand | 47.18 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 9000.00 | 8.81 Million | 15.58 Million | 65.69 Million | 2000.00 | 50.09 Million |
| Other Financing Activities | -98 Thousand | -169 Thousand | 3.33 Million | -3.65 Million | -420 Thousand | -2.91 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 2.37 Million | -560 Thousand | -3.53 Million | 450 Thousand | 796 Thousand | -106 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 319 Thousand | -808 Thousand | -846 Thousand | -5.33 Million | 424 Thousand | -855 Thousand |
| Cash at beginning of period | 15.79 Million | 22.35 Million | 24.85 Million | 32.54 Million | 55.75 Million | 23.41 Million |
| Cash at end of period | 31.9 Million | 15.79 Million | 22.35 Million | 22.35 Million | 26.24 Million | 55.75 Million |
| Capital Expenditure | -196 Thousand | -2.14 Million | -787 Thousand | -1.04 Million | -144 Thousand | -71 Thousand |
| Effect of forex changes on cash | - | - | - | 1.00 | - | - |
| Net cash flow / Change in cash | 16.1 Million | -6.55 Million | -2.49 Million | -10.19 Million | -29.51 Million | 32.34 Million |
| Free Cash Flow | -20.17 Million | -24.6 Million | -19.84 Million | -64.35 Million | -14.25 Million | -14.35 Million |
AMNF
2466
BIM
ASPN
1321
601880